BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//BioCatalystFeed//bcf//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BioCatalystFeed MRK catalysts
X-WR-CALDESC:Scheduling/reference data from public records\; dates can move
 . Not investment\, legal or medical advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:e4f78a1429f6367d6e4a@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261120
DTEND;VALUE=DATE:20261121
SUMMARY:MRK P3 readout (est.): Study of Pembrolizumab (MK-3475) in Combinat
 ion With Adjuvant Chemotherapy With or Without Radiotherapy in Participant
 s With Newly Diagnosed Endometrial Cancer After Surgery With Curative Inte
 nt (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
DESCRIPTION:Study of Pembrolizumab (MK-3475) in Combination With Adjuvant C
 hemotherapy With or Without Radiotherapy in Participants With Newly Diagno
 sed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / K
 EYNOTE-B21 / ENGOT-en11 / GOG-3053)\nNCT04634877 | PHASE3 | ACTIVE_NOT_REC
 RUITING | sponsor: Merck Sharp & Dohme LLC\nPrimary completion date (ESTIM
 ATED)\; top-line results usually follow later.\nTicker MRK (confidence 0.6
 )\nSource: https://clinicaltrials.gov/study/NCT04634877\nScheduling/refere
 nce data from public records\; dates can move. Not investment\, legal or m
 edical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT04634877
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:0e24b2c05fc383b9165e@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261222
DTEND;VALUE=DATE:20261223
SUMMARY:MRK P1/P2 readout (est.): A Study of Belzutifan (MK-6482) in Combin
 ation With Palbociclib Versus Belzutifan Monotherapy in Participants With 
 Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024)
DESCRIPTION:A Study of Belzutifan (MK-6482) in Combination With Palbociclib
  Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Ca
 rcinoma (MK-6482-024/LITESPARK-024)\nNCT05468697 | PHASE1/PHASE2 | ACTIVE_
 NOT_RECRUITING | sponsor: Merck Sharp & Dohme LLC\nPrimary completion date
  (ESTIMATED)\; top-line results usually follow later.\nTicker MRK (confide
 nce 0.6)\nSource: https://clinicaltrials.gov/study/NCT05468697\nScheduling
 /reference data from public records\; dates can move. Not investment\, leg
 al or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05468697
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:f6672bf68d76b66982bc@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270112
DTEND;VALUE=DATE:20270113
SUMMARY:MRK P3 readout (est.): Study of Pembrolizumab (MK-3475) Monotherapy
  Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Partic
 ipants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed 
 Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D
 46)
DESCRIPTION:Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab
  Govitecan in Combination With Pembrolizumab for Participants With Metasta
 tic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1
  (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)\nNCT05609968 | 
 PHASE3 | ACTIVE_NOT_RECRUITING | sponsor: Merck Sharp & Dohme LLC\nPrimary
  completion date (ESTIMATED)\; top-line results usually follow later.\nTic
 ker MRK (confidence 0.6)\nSource: https://clinicaltrials.gov/study/NCT0560
 9968\nScheduling/reference data from public records\; dates can move. Not 
 investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05609968
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:71d283bb82a17269e6aa@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270115
DTEND;VALUE=DATE:20270116
SUMMARY:MRK P3 readout (est.): Efficacy Against Oral Persistent Infection\,
  Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9
 vHPV) in Men Aged 20-45 Years (V503-049)
DESCRIPTION:Efficacy Against Oral Persistent Infection\, Immunogenicity and
  Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 2
 0-45 Years (V503-049)\nNCT04199689 | PHASE3 | ACTIVE_NOT_RECRUITING | spon
 sor: Merck Sharp & Dohme LLC\nPrimary completion date (ESTIMATED)\; top-li
 ne results usually follow later.\nTicker MRK (confidence 0.6)\nSource: htt
 ps://clinicaltrials.gov/study/NCT04199689\nScheduling/reference data from 
 public records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT04199689
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:2a784a66cade349cd9c3@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:MRK P3 readout (est.): Efficacy and Safety of Pembrolizumab (MK-347
 5) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-
 invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)
DESCRIPTION:Efficacy and Safety of Pembrolizumab (MK-3475) in Combination W
 ith Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Ca
 ncer (MIBC) (MK-3475-992/KEYNOTE-992)\nNCT04241185 | PHASE3 | ACTIVE_NOT_R
 ECRUITING | sponsor: Merck Sharp & Dohme LLC\nPrimary completion date (EST
 IMATED)\; top-line results usually follow later.\nTicker MRK (confidence 0
 .6)\nSource: https://clinicaltrials.gov/study/NCT04241185\nScheduling/refe
 rence data from public records\; dates can move. Not investment\, legal or
  medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT04241185
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:9732df1c46890ff99cbc@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270212
DTEND;VALUE=DATE:20270213
SUMMARY:MRK P2 readout (est.): Safety and Efficacy of Pembrolizumab (MK-347
 5) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-6
 67/KEYNOTE-667)
DESCRIPTION:Safety and Efficacy of Pembrolizumab (MK-3475) in Children and 
 Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)\nNC
 T03407144 | PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: Merck Sharp & Dohme 
 LLC\nPrimary completion date (ESTIMATED)\; top-line results usually follow
  later.\nTicker MRK (confidence 0.6)\nSource: https://clinicaltrials.gov/s
 tudy/NCT03407144\nScheduling/reference data from public records\; dates ca
 n move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT03407144
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:ef28db6d51eff94c6fd8@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270217
DTEND;VALUE=DATE:20270218
SUMMARY:MRK P2 readout (est.): Study to Evaluate Tulisokibart in Adults Wit
 h Psoriatic Arthritis (MK-7240-015)
DESCRIPTION:Study to Evaluate Tulisokibart in Adults With Psoriatic Arthrit
 is (MK-7240-015)\nNCT07486960 | PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: 
 Merck Sharp & Dohme LLC\nPrimary completion date (ESTIMATED)\; top-line re
 sults usually follow later.\nTicker MRK (confidence 0.6)\nSource: https://
 clinicaltrials.gov/study/NCT07486960\nScheduling/reference data from publi
 c records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07486960
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:514ca414165bf506bb10@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261016
DTEND;VALUE=DATE:20261017
SUMMARY:MRK APPROVAL: KEYTRUDA
DESCRIPTION:Approved 2026-10-16: KEYTRUDA (BLA125514 SUPPL191)\nConfidence:
  confirmed\nTicker MRK (confidence 0.6)\nSource: https://www.accessdata.fd
 a.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514\nSch
 eduling/reference data from public records\; dates can move. Not investmen
 t\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=125514
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:471a042ff4f3e9deb2d0@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261016
DTEND;VALUE=DATE:20261017
SUMMARY:MRK APPROVAL: KEYTRUDA QLEX
DESCRIPTION:Approved 2026-10-16: KEYTRUDA QLEX (BLA761467 SUPPL8)\nConfiden
 ce: confirmed\nTicker MRK (confidence 0.6)\nSource: https://www.accessdata
 .fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761467\n
 Scheduling/reference data from public records\; dates can move. Not invest
 ment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761467
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:d64c41c76b91f40802e7@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261014
DTEND;VALUE=DATE:20261015
SUMMARY:MRK APPROVAL: ENFLONSIA
DESCRIPTION:Approved 2026-10-14: ENFLONSIA (BLA761432 SUPPL3)\nConfidence: 
 confirmed\nTicker MRK (confidence 0.6)\nSource: https://www.accessdata.fda
 .gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761432\nSche
 duling/reference data from public records\; dates can move. Not investment
 \, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761432
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:427d9e08d1252f4cf6db@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260924
DTEND;VALUE=DATE:20260925
SUMMARY:MRK APPROVAL: WELIREG
DESCRIPTION:Approved 2026-09-24: WELIREG (NDA215383 SUPPL13)\nConfidence: c
 onfirmed\nTicker MRK (confidence 0.6)\nSource: https://www.accessdata.fda.
 gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215383\nSched
 uling/reference data from public records\; dates can move. Not investment\
 , legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=215383
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:dff45e0ec0fb6cdffbe2@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260921
DTEND;VALUE=DATE:20260922
SUMMARY:MRK APPROVAL: WINREVAIR
DESCRIPTION:Approved 2026-09-21: WINREVAIR (BLA761363 SUPPL12)\nConfidence:
  confirmed\nTicker MRK (confidence 0.6)\nSource: https://www.accessdata.fd
 a.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761363\nSch
 eduling/reference data from public records\; dates can move. Not investmen
 t\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761363
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:94b359b26e148ba1261b@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260710
DTEND;VALUE=DATE:20260711
SUMMARY:MRK APPROVAL: KEYTRUDA
DESCRIPTION:Approved 2026-07-10: KEYTRUDA (BLA125514 SUPPL194)\nConfidence:
  confirmed\nTicker MRK (confidence 0.6)\nSource: https://www.accessdata.fd
 a.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514\nSch
 eduling/reference data from public records\; dates can move. Not investmen
 t\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=125514
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:64f8cddced87634dca26@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260710
DTEND;VALUE=DATE:20260711
SUMMARY:MRK APPROVAL: KEYTRUDA QLEX
DESCRIPTION:Approved 2026-07-10: KEYTRUDA QLEX (BLA761467 SUPPL12)\nConfide
 nce: confirmed\nTicker MRK (confidence 0.6)\nSource: https://www.accessdat
 a.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761467\
 nScheduling/reference data from public records\; dates can move. Not inves
 tment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761467
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:618657e9bd95e4cf0024@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260624
DTEND;VALUE=DATE:20260625
SUMMARY:MRK APPROVAL: KEYTRUDA
DESCRIPTION:Approved 2026-06-24: KEYTRUDA (BLA125514 SUPPL187)\nConfidence:
  confirmed\nTicker MRK (confidence 0.6)\nSource: https://www.accessdata.fd
 a.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514\nSch
 eduling/reference data from public records\; dates can move. Not investmen
 t\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=125514
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:a34eee5dc0758d8a9002@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260624
DTEND;VALUE=DATE:20260625
SUMMARY:MRK APPROVAL: KEYTRUDA QLEX
DESCRIPTION:Approved 2026-06-24: KEYTRUDA QLEX (BLA761467 SUPPL4)\nConfiden
 ce: confirmed\nTicker MRK (confidence 0.6)\nSource: https://www.accessdata
 .fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761467\n
 Scheduling/reference data from public records\; dates can move. Not invest
 ment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761467
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:b666c9183b939f527cf8@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260612
DTEND;VALUE=DATE:20260613
SUMMARY:MRK APPROVAL: WELIREG
DESCRIPTION:Approved 2026-06-12: WELIREG (NDA215383 SUPPL15)\nConfidence: c
 onfirmed\nTicker MRK (confidence 0.6)\nSource: https://www.accessdata.fda.
 gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215383\nSched
 uling/reference data from public records\; dates can move. Not investment\
 , legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=215383
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:897ca66b05ba98af9730@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260612
DTEND;VALUE=DATE:20260613
SUMMARY:MRK APPROVAL: KEYTRUDA
DESCRIPTION:Approved 2026-06-12: KEYTRUDA (BLA125514 SUPPL192)\nConfidence:
  confirmed\nTicker MRK (confidence 0.6)\nSource: https://www.accessdata.fd
 a.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514\nSch
 eduling/reference data from public records\; dates can move. Not investmen
 t\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=125514
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:5f19dc43526498f4bcf9@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260612
DTEND;VALUE=DATE:20260613
SUMMARY:MRK APPROVAL: KEYTRUDA QLEX
DESCRIPTION:Approved 2026-06-12: KEYTRUDA QLEX (BLA761467 SUPPL9)\nConfiden
 ce: confirmed\nTicker MRK (confidence 0.6)\nSource: https://www.accessdata
 .fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761467\n
 Scheduling/reference data from public records\; dates can move. Not invest
 ment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761467
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:b43b5db0174e1ba3a60f@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260424
DTEND;VALUE=DATE:20260425
SUMMARY:MRK APPROVAL: KEYTRUDA QLEX
DESCRIPTION:Approved 2026-04-24: KEYTRUDA QLEX (BLA761467 SUPPL3)\nConfiden
 ce: confirmed\nTicker MRK (confidence 0.6)\nSource: https://www.accessdata
 .fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761467\n
 Scheduling/reference data from public records\; dates can move. Not invest
 ment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761467
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:0868a027edadc7d94eee@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260210
DTEND;VALUE=DATE:20260211
SUMMARY:MRK APPROVAL: KEYTRUDA
DESCRIPTION:Approved 2026-02-10: KEYTRUDA (BLA125514 SUPPL186)\nConfidence:
  confirmed\nTicker MRK (confidence 0.6)\nSource: https://www.accessdata.fd
 a.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514\nSch
 eduling/reference data from public records\; dates can move. Not investmen
 t\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=125514
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:fb3516a10709f94730c9@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260210
DTEND;VALUE=DATE:20260211
SUMMARY:MRK APPROVAL: KEYTRUDA QLEX
DESCRIPTION:Approved 2026-02-10: KEYTRUDA QLEX (BLA761467 SUPPL2)\nConfiden
 ce: confirmed\nTicker MRK (confidence 0.6)\nSource: https://www.accessdata
 .fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761467\n
 Scheduling/reference data from public records\; dates can move. Not invest
 ment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761467
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:970cb607b770d7619cc6@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260127
DTEND;VALUE=DATE:20260128
SUMMARY:MRK APPROVAL: NOXAFIL
DESCRIPTION:Approved 2026-01-27: NOXAFIL (NDA205053 SUPPL18)\nConfidence: c
 onfirmed\nTicker MRK (confidence 0.6)\nSource: https://www.accessdata.fda.
 gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205053\nSched
 uling/reference data from public records\; dates can move. Not investment\
 , legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=205053
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:70af68e087da88f68c8c@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260127
DTEND;VALUE=DATE:20260128
SUMMARY:MRK APPROVAL: NOXAFIL
DESCRIPTION:Approved 2026-01-27: NOXAFIL (NDA205596 SUPPL21)\nConfidence: c
 onfirmed\nTicker MRK (confidence 0.6)\nSource: https://www.accessdata.fda.
 gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205596\nSched
 uling/reference data from public records\; dates can move. Not investment\
 , legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=205596
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:b233343ca30a18409966@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20251121
DTEND;VALUE=DATE:20251122
SUMMARY:MRK APPROVAL: KEYTRUDA
DESCRIPTION:Approved 2025-11-21: KEYTRUDA (BLA125514 SUPPL188)\nConfidence:
  confirmed\nTicker MRK (confidence 0.6)\nSource: https://www.accessdata.fd
 a.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514\nSch
 eduling/reference data from public records\; dates can move. Not investmen
 t\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=125514
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:1924721e9e05650032ea@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20251121
DTEND;VALUE=DATE:20251122
SUMMARY:MRK APPROVAL: KEYTRUDA QLEX
DESCRIPTION:Approved 2025-11-21: KEYTRUDA QLEX (BLA761467 SUPPL1)\nConfiden
 ce: confirmed\nTicker MRK (confidence 0.6)\nSource: https://www.accessdata
 .fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761467\n
 Scheduling/reference data from public records\; dates can move. Not invest
 ment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761467
CATEGORIES:approval,confirmed
END:VEVENT
END:VCALENDAR
